Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 24, 2017
What is the patent landscape for Janumet Xr, and what generic Janumet Xr alternatives are available?
Janumet Xr is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.| Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 1 |
| Clinical Trials: see list | 8 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | JANUMET XR at DailyMed |
| Ingredient-type | Biguanides |
| Drug Class | Dipeptidyl Peptidase 4 Inhibitor Biguanide |
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| sitagliptin phosphate and metformin hydrochloride | Extended-release Tablets | 100 mg/1000 mg | Janumet XR | 10/22/2012 |
| sitagliptin phosphate and metformin hydrochloride | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | Janumet XR | 3/16/2012 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,168,637 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes | ► Subscribe | |||||||||||||
| 7,829,530 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 7,157,429 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 6,803,357 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 9,044,424 | Methods of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 8,440,668 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes | ► Subscribe | |||||||||||||
| 8,513,190 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 8,318,669 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2364845 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 03004498 | ► Subscribe | |||||||||||||
| Serbia | 51873 | ► Subscribe | |||||||||||||
| Australia | 2004253889 | ► Subscribe | |||||||||||||
| Austria | 373003 | ► Subscribe | |||||||||||||
| Japan | 2005505531 | ► Subscribe | |||||||||||||
| Argentina | 094185 | ► Subscribe | |||||||||||||
| China | 1269528 | ► Subscribe | |||||||||||||
| Norway | 321999 | ► Subscribe | |||||||||||||
| Taiwan | I347185 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2007 | Austria | ► Subscribe | PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001-018 (MITTEILUNG) 20070323 | ||||||||||||
| 2014000071 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 | ||||||||||||
| 0287 | Netherlands | ► Subscribe | 300287, 20220705, EXPIRES: 20220320 | ||||||||||||
| 2014045 | Lithuania | ► Subscribe | PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919 | ||||||||||||
| 2014 00066 | Denmark | ► Subscribe | PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919 | ||||||||||||
| 00677 | Netherlands | ► Subscribe | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 | ||||||||||||
| 0308 | Netherlands | ► Subscribe | 300308, 20170424, EXPIRES: 20220423 | ||||||||||||
| 2014043 | Lithuania | ► Subscribe | PRODUCT NAME: SAXAGLIPTINUM; REGISTRATION NO/DATE: EU/1/09/545/001-015 20091001 | ||||||||||||
| 2014000070 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 | ||||||||||||
| 2014 00037 | Denmark | ► Subscribe | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,760 others who get our Drug Patent Expiration Alerts:
